Regenxbio gives glimpse at early Duchenne gene therapy results, plans pivotal study for accelerated approval

Lei Lei Wu

News Reporter

Regenxbio shared early biomarker results from a 12-year-old boy with Duchenne muscular dystrophy who received a higher dose of its gene therapy, and the biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regenxbio gives glimpse at early Duchenne gene therapy results, plans pivotal study for accelerated approval

Lei Lei Wu

News Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Re­genxbio gives glimpse at ear­ly Duchenne gene ther­a­py re­sults, plans piv­otal study for ac­cel­er­at­ed ap­proval

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Regenxbio gives glimpse at early Duchenne gene therapy results, plans pivotal study for accelerated approval

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings